LLY Jan 2025 660.000 call
- Yahoo Finance Video
FDA panel votes to recommend Eli Lilly's Alzheimer's drug
A US Food and Drug Administration (FDA) panel voted unanimously 11-0 to recommend the approval of Eli Lilly's (LLY) Alzheimer's drug, donanemab. Yahoo Finance's Anjalee Khemlani reports more on the story and the drug's ability to slow cognitive decline. Read more about donanemab here. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Melanie Riehl
- Investor's Business Daily
FDA Panelists Unanimously Back Eli Lilly's Biogen-Rivaling Alzheimer's Drug
Eli Lilly stock jumped Monday after FDA advisors said the benefits of Alzheimer's treatment donanemab outweigh the risks for most patients.
- Associated Press Finance
Alzheimer's drug that can slow disease gets backing from FDA advisers
A closely watched Alzheimer's drug from Eli Lilly won the backing of federal health advisers on Monday, setting the stage for the treatment's expected approval for people with mild dementia caused by the brain-robbing disease. Food and Drug Administration advisers voted unanimously that the drug's ability to slow the disease outweighs its risks, including side effects like brain swelling and bleeding that will have to be monitored. The FDA will make the final decision on approval later this year.
